Lung Cancer Canada is collecting data to support approval of crizotinib for ROS1+ non-small cell lung cancer in their country. Their deadline for submission is rapidly approaching, and they need more data to strengthen their case.

They would like ROS1+ patients who have taking crizotinib to share the following information (no names):

• Demographic data (e.g., age, gender, date of diagnosis)
• If currently or previously on crizotinib and for how long
• Responses to crizotinib (e.g., reduction in size of tumor, no response, cancer progression)
• Duration of the response
• Side effects (what type, have they resolved, if yes, how)

Please email your responses immediately to Iwo Effiong at iwo@LungCancerCanada.ca.

Thank you for helping more ROS1 patients obtain access to crizotinib!